Increased Donor‐Derived Cell‐Free DNA as a Predictor for the Early Detection of Antibody‐Mediated Rejection Following Heart Transplantation
Clinical Transplantation · 2025
DOI: 10.1111/ctr.70209 ↗At a glance
Journal article in Clinical Transplantation, 2025. Written by Dana Dlouha and 6 co-authors. Institution: Experimental Medicine Center, Institute of Clinical and Experimental Medicine, Prague, Czech Republic. Major MEDLINE topics: Heart Transplantation, Graft Rejection, Cell-Free Nucleic Acids, Tissue Donors. Cited 4 times so far (Crossref); 23 references. Funded by: the Ministry of Health of the Czech Republic, the Ministry of Health of the Czech Republic-DRO, Institute for Clinical and Experimental Medicine-IKEM.
Abstract (original language)
Plasma circulating donor‐derived cell‐free DNA (ddcfDNA) can be used to noninvasively monitor acute rejection of heart transplants (HTx). This study utilized digital droplet PCR to analyze ddcfDNA concentrations (measured in copies per milliliter) and the fractional abundance (%ddcfDNA) to differentiate between donor and recipient DNA on the basis of single nucleotide polymorphism (SNP) homozygosity. Seventy‐seven patients participated in a study, providing 300 plasma samples. Both markers, mean ddcfDNA (cp/mL) and %ddcfDNA, showed similar decreasing trends following the HTx, ( R 2 < 0.2; p < 0.001). Significantly higher levels of ddcfDNA (cp/mL) and %ddcfDNA were observed during episodes of acute rejection (AR) compared to non‐rejection samples ( p < 0.001). Additionally, antibody‐mediated rejection (AMR) was associated with increased %ddcfDNA levels compared to non‐rejection and to acute cellular rejection samples ( p < 0.001 and p < 0.01). A logistic regression model identified %ddcfDNA as an early predictor of AMR risk 10–19 days post‐heart transplant (odds ratio 158, p < 0.02). Performance analysis established an optimal %ddcfDNA threshold of 0.125% for AMR detection, correctly identifying all patients without subsequent AMR. These findings suggest that early %ddcfDNA measurements post‐HTx can accurately identify individuals unlikely to develop AMR during the first posttransplant year.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Experimental Medicine Center, Institute of Clinical and Experimental Medicine, Prague, Czech Republic.
- Department of Data Science, Institute of Clinical and Experimental Medicine, Prague, Czech Republic.
- Cardio Center, Institute of Clinical and Experimental Medicine, Prague, Czech Republic.
- Laboratory of Genomics and Bioinformatics, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.
- Third Department of Internal Medicine, First Faculty of Medicine, Charles University, Prague, Czech Republic.
ORCID profiles: Dana Dlouha, Jaroslav Alois Hubacek
Funding
- the Ministry of Health of the Czech Republic
- the Ministry of Health of the Czech Republic-DRO
- Institute for Clinical and Experimental Medicine-IKEM
Cite
APA
Dlouha, D., Chytilova, S., Vymetalova, J., Rohlova, E., Lukasova, M., Novakova, S., & Hubacek, J. A. (2025). Increased Donor‐Derived Cell‐Free DNA as a Predictor for the Early Detection of Antibody‐Mediated Rejection Following Heart Transplantation. Clinical Transplantation. https://doi.org/10.1111/ctr.70209
Vancouver
Dlouha D, Chytilova S, Vymetalova J, Rohlova E, Lukasova M, Novakova S, et al. Increased Donor‐Derived Cell‐Free DNA as a Predictor for the Early Detection of Antibody‐Mediated Rejection Following Heart Transplantation. Clinical Transplantation. 2025. doi:10.1111/ctr.70209
BibTeX
@article{Dlouha2025,
author = {Dlouha, Dana and Chytilova, Sarka and Vymetalova, Jevgenija and Rohlova, Eva and Lukasova, Marianna and Novakova, Sarka and Hubacek, Jaroslav Alois},
title = {Increased Donor‐Derived Cell‐Free DNA as a Predictor for the Early Detection of Antibody‐Mediated Rejection Following Heart Transplantation},
journal = {Clinical Transplantation},
year = {2025},
doi = {10.1111/ctr.70209}
}
EUVIMED